SAN DIEGO, May 12, 2021 – Qpex Biopharma, Inc., (Qpex) a resistance-focused clinical-stage biopharmaceutical company discovering and developing innovative anti-infective therapies, announced that the first patient has been dosed in a Phase 1 study of ORAvance™, an ultra-broad-spectrum oral beta-lactamase inhibitor for use in combination with beta-lactam antibiotics for drug-resistant gram-negative bacterial infections.
Vu L. Truong, Ph.D.
Founder, Chief Executive Officer and Director
Aridis Pharmaceuticals
Dr. Truong is a founder of Aridis and was elected CEO in 2014 after having served as the company’s Chief Scientific Officer since 2005. He has more than 20 years of experience in biopharmaceutical drug development, having held positions of increasing responsibilities in companies which were eventually acquired by larger entities, including Gene Medicine (sold to Megabios), Aviron (sold to MedImmune) and MedImmune (sold to Astra Zeneca). Having maintained a life-long interest in infectious diseases, he has focused on researching and developing innovative human monoclonal antibodies and vaccines designed to address life-threatening infections. His product development experience includes FluMist™, Synagis™ mAb and a number of other monoclonal antibody-based therapeutics. Dr. Truong is the principal architect of Aridis’ technologies, which includes a range of anti-infective products and pharmaceutical processing technologies. He received his Ph.D. in Pharmacology and Molecular Sciences at the Johns Hopkins University School of Medicine.
René Russo, PharmD, BCPS
Roger J. Pomerantz, M.D., F.A.C.P.
Christine Ann Miller
Graham G. Lumsden
Marco Taglietti, M.D.
Ankit Mahadevia
John McDonough
Frank Pasqualone
Ed Garvey
Vijay B. Samant
Jeffrey Stein, Ph.D.
Evan Loh, M.D.
Michael Dunne, M.D
Ciara Kennedy, Ph.D.
Ted Schroeder
Kevin Finney
Stephen Conafay
Christopher J. Burns, Ph.D.
Corey Fishman